Health

Post-Doctoral Fellowships

France

Pharmacodiversity Oriented Synthesis: A New Tool For The Rapid Discovery Of Treatment For Multidrug-Resistant Bacteria

The threat posed by drug-resistant bacteria and other microbes is increasing as new strains emerge. Yet, major pharmaceutical companies are not seeking new drugs to fight back. Dr. Andrew Silvanus is developing a faster, easier method of screening candidates for potential new “superdrugs”: starting with natural substances containing molecular structures already known to fight infection, tweaking them in a variety of ways, and testing the results. Silvanus's work has the potential to accelerate vital antibiotic discovery.

Antibiotic Resistance: Finding New Drugs Faster

To add or modify information on this page, please contact us at the following address: community.research@axa.com

Andrew Christopher
SILVANUS

Institution

Université de Versailles Saint-Quentin-en-Yvelines

Country

France

Nationality

British